Efficacy Maxinom® And Maxitrol® in Reducing The Signs And Symptoms Of Acute Bacterial Conjunctivitis

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to evaluate, through clinical parameters, the effectiveness of your medicine topic Maxinom ® (dexamethasone, neomycin and polymyxin B - Union Chemicals), comparing it to the topical medication Maxitrol ® (dexamethasone, neomycin and polymyxin B - Alcon ) by the percentage of improvement (sustained response rate) at the end of treatment, among the products studied.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Azidus Brasil
• Treatments: Bacitracin; Bacitracin zinc, neomycin sulfate, polymyxin B, drug combination; BB 1101; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Dexamethasone, neomycin, polymyxin B drug combination; Fluprednisolone; Neomycin; Polymyxin B; Polymyxins

Criteria

Inclusion Criteria:

• Patients who agree with all study procedures and sign, by his own free will, IC;

• Adult patients, regardless of gender, ethnicity or social status, with good mental health;

• Patients who present at screening visit, picture of acute bacterial conjunctivitis diagnosed clinically.

Exclusion Criteria:

• Patients with clinical diagnosis or suspicion of conjunctivitis due to any process that is not due to bacterial infection, such as infections by fungi, protozoa, viruses and allergic conjunctivitis;

• Patients with known hypersensitivity to any component of the formulas of the study drugs;

• Patients with a history or clinical diagnosis of other lesions that may affect the outcome, such as glaucoma, corneal ulcer or scars;

• Concomitant use of ocular medication other than the study;

• Pregnant or lactating women;

• Being or having been treated for any type of conjunctivitis within 15 days and have finished treatment or less than 07 days